ApoB Goal Cost-Effective in Primary Prevention - Summary - MDSpire
From the Journals

ApoB Goal Cost-Effective in Primary Prevention

Strategy increased quality-adjusted life-years and showed favorable cost-effectiveness vs low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol goals

Share

A simulation study found that using an apolipoprotein B (apoB) target for lipid-lowering therapy in primary prevention is more effective than targeting non–high-density lipoprotein cholesterol (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C). Conducted among 250,000 statin-eligible adults, the apoB strategy resulted in 1,324 additional quality-adjusted life-years (QALYs) and was cost-effective at an incremental cost-effectiveness ratio of $30,300 per QALY. Higher treatment intensification rates and greater ASCVD event prevention were also observed with this method.

Original Source(s)

ApoB Goal Cost-Effective in Primary Prevention

  • by Kathryn Wighton

  • April 15, 2026

Related Content

Retinal Imaging Model Aids CAD Detection

Fundus-based model showed moderate-to-good accuracy and improved performance when combined with clinical risk factors in a high-risk cohort

Is Long COVID Affecting the Heart?

Study points to increased cardiovascular events post-infection

  • April 17, 2026

  • 2 min
Top 10 Evidence-Based Essentials in Cardiology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice